Developer docs
API playgroundTry for free, no card

Search company profiles

Iovance Biotherapeutics

Full company profile

uuid0000kne

Namestring
Iovance Biotherapeutics
Legal namestring
Iovance Biotherapeutics, Inc.
Websiteurl
iovance.com
Company typeenum
Public
Founded yearint
2016
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersSan Carlos, United States
HQ citystring
San Carlos
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy, tumor infiltrating lymphocytes, autologous immunotherapy, oncology biopharmaceuticals, solid tumor treatments
Industry4 codes
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cell Therapy Immunotherapy
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Amtagvi (lifileucel) Sales
TypeOne Time License
Description

One-time autologous TIL cell therapy for advanced melanoma. Revenue from commercial product sales to authorized treatment centers. FY2025 revenue: $263.5 million, up 60.6% year-over-year. Q1 2026 revenue: $60 million. List price: $563,000 (as of 2026).

fool.com
2Proleukin (aldesleukin) Sales
TypeOne Time License
Description

Acquired from Clinigen in May 2023, Proleukin is used as supportive care in TIL treatment regimens. Q1 2026 contributed $11 million in revenue. Distributed through specialty pharmacy partnerships globally.

stocktitan.net
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Pricing details1 tier
1Amtagvi one-time treatment list price: $563,000
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

One-time autologous TIL cell therapy. List price increased from $515,000 at FDA approval (February 2024) to $563,000 by 2026. Actual reimbursement varies by payer; Medicare covers the therapy with specific coverage criteria. Patient assistance programs available through IovanceCares.

inquirer.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Amtagvi
Description

FDA-approved tumor infiltrating lymphocyte therapy (lifileucel) for advanced melanoma. Product website: www.amtagvi.com

iovance.com
+3 more records
Core offering1 text field

Iovance develops, manufactures, and commercializes autologous tumor infiltrating lymphocyte (TIL) cell therapies for the treatment of solid tumor cancers. Its flagship commercial product is Amtagvi (lifileucel), the first FDA-approved one-time T-cell therapy for solid tumors, indicated for advanced melanoma. The company also sells Proleukin (aldesleukin) as supportive care used within the TIL regimen, and is advancing a pipeline extending the same TIL platform to NSCLC, endometrial, cervical, head and neck, and soft tissue sarcoma indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 44-52% objective response rate in advanced melanoma (real-world data), versus 31% in original C-144-01 clinical trial
+5 more records
Product overview1 text field

Iovance Biotherapeutics is a commercial-stage biopharmaceutical company offering a portfolio of tumor infiltrating lymphocyte (TIL) cell therapies. The core commercial products are Amtagvi® (lifileucel), the first FDA-approved individualized T-cell therapy for solid tumors (advanced melanoma), and Proleukin® (aldesleukin), acquired to support the TIL treatment regimen. The company operates a pipeline-in-a-drug strategy with lifileucel being studied across multiple solid tumor indications (NSCLC, cervical, endometrial, sarcoma, HNSCC), alongside next-generation TIL therapies including genetically modified IOV-4001 (PD-1 knockout via TALEN®), IOV-5001 (IL-12 tethered), and LN-145 Gen 3 (accelerated 16-day manufacturing). All TIL therapies are manufactured at the company's centralized 136,000 sq ft Iovance Cell Therapy Center (iCTC) in Philadelphia using proprietary Gen 2 processes.

Product and service7 records
1Amtagvi (lifileucel)
CategoryCommercial cell therapy product (oncology)
Description

One-time, tumor-derived autologous T-cell immunotherapy (TIL therapy) for adult patients with unresectable or metastatic melanoma previously treated with anti-PD-1 therapy and, if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. Manufactured at iCTC Philadelphia and administered at authorized treatment centers with NMA-LD lymphodepletion and IL-2 support.

2Proleukin (aldesleukin)
CategorySupportive care pharmaceutical (oncology)
Description

Interleukin-2 (IL-2) therapy used as supportive care within the TIL treatment regimen to promote T-cell activity and persistence after TIL infusion. Acquired from Clinigen and distributed by Iovance through authorized treatment centers globally alongside Amtagvi.

3Lifileucel (LN-145)
CategoryInvestigational cell therapy pipeline product
Description

Investigational autologous TIL therapy being evaluated across multiple solid tumor indications beyond the approved advanced melanoma setting, supporting Iovance's pipeline-in-a-drug strategy.

4IOV-4001 (PD-1 knockout TIL)
CategoryInvestigational gene-edited cell therapy pipeline product
Description

Genetically modified autologous TIL therapy with the PD-1 gene inactivated using TALEN gene-editing technology licensed from Cellectis, designed to restore T-cell ability to kill cancer cells by avoiding checkpoint inhibition.

5IOV-5001 (IL-12 tethered TIL)
CategoryInvestigational engineered cell therapy pipeline product
Description

Next-generation IL-12 tethered TIL cell therapy designed to express IL-12 only upon antigen encounter within the tumor microenvironment and tether it to the cell membrane to avoid systemic toxicity, remodeling the tumor microenvironment into an immuno-supportive state.

6LN-145 Gen 3 (16-day manufacturing)
CategoryInvestigational next-generation cell therapy pipeline product
Description

Third-generation TIL therapy using Iovance's proprietary 16-day GMP manufacturing process to reduce vein-to-vein time between tumor sample collection and infusion for patients, currently being explored in clinical trials.

7IOV-3001 (modified IL-2 analog)
CategoryInvestigational supportive care biologic pipeline product
Description

Second-generation modified IL-2 fusion protein (modified aldesleukin fused to a humanized monoclonal IgG1K antibody) licensed from Novartis, designed to enhance TIL survival and cellular proliferation with a potentially better safety profile and less frequent dosing compared to Proleukin.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-15
Description

Specialty pharmacy partnership for Amtagvi product distribution in the United States. InspiroGene manages product fulfillment, cold chain logistics for the temperature-sensitive autologous cell therapy, and reimbursement support services.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-05-01
Description

In May 2023, Iovance acquired worldwide rights to Proleukin (aldesleukin) from Clinigen to strengthen its T-cell immunotherapy programs for advanced melanoma patients. Proleukin is used as supportive care in TIL treatment regimens and is now distributed through Iovance's commercial infrastructure.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-01-01
Description

In January 2020, Iovance and Cellectis entered into a research collaboration and worldwide license agreement enabling Iovance to use certain TALEN gene-editing technologies to modify TIL for therapeutic use in several cancer types. Iovance has a preclinical pipeline of TALEN-edited TIL therapies including double-knockout programs. This partnership enables development of next-generation gene-edited TIL products like IOV-4001 (PD-1 knockout TIL).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cooperative Research and Development Agreement (CRADA) with Dr. Steven Rosenberg for development of TIL therapy alone or in combination with other agents for metastatic melanoma, bladder, lung, breast, and HPV-associated cancers. Also includes TIL + anti-PD-1 combination clinical trial for melanoma treatment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

TIL + anti-PD-1 antibody combination therapy clinical trial in non-small cell lung cancer (NSCLC). Also conducting TIL clinical trial in adolescents and young adults with soft tissue sarcoma.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

TIL clinical trials to treat ovarian cancer, sarcomas, pancreatic cancer, and colorectal cancer. MD Anderson is one of the leading comprehensive cancer centers participating in Iovance's clinical development program.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

TIL clinical trial to treat triple-negative breast cancer (TNBC). Academic collaboration advancing TIL therapy in an area of high unmet medical need.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major pharmaceutical company with Kymriah (first FDA-approved CAR-T) and licensing partner for Iovance's IOV-3001 modified IL-2 analog. Broad incumbent in cell therapy with established manufacturing capabilities and competing immuno-oncology portfolio.

TypeEmerging player
Description

Clinical-stage gene editing company developing allogeneic CAR-T and TALEN-edited cell therapies. Iovance's technology partner for PD-1 knockout TIL (IOV-4001), making it a strategic peer and indirect competitor in gene-edited cell therapies.

3Turnstone Biologics
TypeDirect peer
Description

Clinical-stage biotech developing next-generation tumor-infiltrating lymphocyte (TIL) therapies for solid tumors, including selected TIL technology. Comparable as a TIL-focused competitor with similar autologous cell therapy development approach.

TypeBroad incumbent
Description

Major pharmaceutical company with Keytruda (pembrolizumab) checkpoint inhibitor that Iovance combines with TIL therapy in TILVANCE-301. Broad incumbent and key strategic partner whose immuno-oncology franchise directly overlaps with Iovance's combination strategies.

TypeDirect peer
Description

Clinical-stage biotechnology company developing autologous TIL therapies (ITIL-306 and ITIL-168) for solid tumors. Direct peer in TIL therapy development with similar manufacturing platform and target indications in melanoma and other solid tumors.

TypeEmerging player
Description

Cell therapy company focused on solid tumor treatment with TIL and CAR-T programs, including technologies to prevent T-cell exhaustion. Emerging peer with overlapping technology focus on T-cell therapies for solid tumors.

7Bristol Myers Squibb
TypeBroad incumbent
Description

Major pharmaceutical company with established CAR-T franchises (Breyanzi, Abecma) and checkpoint inhibitor (Opdivo) competing in melanoma. Broad incumbent in cell therapy and immuno-oncology with overlapping patient populations and significantly larger resources.

TypeBroad incumbent
Description

Through its Kite Pharma subsidiary, Gilead markets Yescarta and Tecartus CAR-T therapies and is a leading cell therapy commercial organization. Broad incumbent with established autologous cell therapy manufacturing infrastructure and cell therapy experience applicable to Iovance's space.

TypeEmerging player
Description

Leading allogeneic CAR-T developer pursuing off-the-shelf cell therapies. Represents a potential competitive threat if allogeneic approaches succeed in solid tumors, contrasting with Iovance's autologous model.

TypeDirect peer
Description

Develops engineered T-cell therapies (SPEAR T-cells) for solid tumors using TCR technology. Directly comparable as a cell therapy company focused on solid tumor cancers with similar autologous manufacturing complexity and clinical development model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Iovance Biotherapeutics

Cell Therapy Immunotherapyiovance.com

Iovance Biotherapeutics firmographics

Firmographics
Name
Iovance Biotherapeutics
Legal name
Iovance Biotherapeutics, Inc.
Website
https://iovance.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

Iovance Biotherapeutics industry classification

Industry
Product category
Cell Therapy Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAH
Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Cell therapy
  • Tumor infiltrating lymphocytes
  • Autologous immunotherapy
  • Oncology biopharmaceuticals
  • Solid tumor treatments

Where Iovance Biotherapeutics is headquartered

Location

Headquarters

HQ city
San Carlos
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Iovance Biotherapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Amtagvi (lifileucel) Sales: One-time autologous TIL cell therapy for advanced melanoma. Revenue from commercial product sales to authorized treatment centers. FY2025 revenue: $263.5 million, up 60.6% year-over-year. Q1 2026 revenue: $60 million. List price: $563,000 (as of 2026).
  2. Proleukin (aldesleukin) Sales: Acquired from Clinigen in May 2023, Proleukin is used as supportive care in TIL treatment regimens. Q1 2026 contributed $11 million in revenue. Distributed through specialty pharmacy partnerships globally.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goAmtagvi one-time treatment list price: $563,000

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Iovance Biotherapeutics product offering

Product offering

Core offering

Iovance develops, manufactures, and commercializes autologous tumor infiltrating lymphocyte (TIL) cell therapies for the treatment of solid tumor cancers. Its flagship commercial product is Amtagvi (lifileucel), the first FDA-approved one-time T-cell therapy for solid tumors, indicated for advanced melanoma. The company also sells Proleukin (aldesleukin) as supportive care used within the TIL regimen, and is advancing a pipeline extending the same TIL platform to NSCLC, endometrial, cervical, head and neck, and soft tissue sarcoma indications.

Product overview

Iovance Biotherapeutics is a commercial-stage biopharmaceutical company offering a portfolio of tumor infiltrating lymphocyte (TIL) cell therapies. The core commercial products are Amtagvi® (lifileucel), the first FDA-approved individualized T-cell therapy for solid tumors (advanced melanoma), and Proleukin® (aldesleukin), acquired to support the TIL treatment regimen. The company operates a pipeline-in-a-drug strategy with lifileucel being studied across multiple solid tumor indications (NSCLC, cervical, endometrial, sarcoma, HNSCC), alongside next-generation TIL therapies including genetically modified IOV-4001 (PD-1 knockout via TALEN®), IOV-5001 (IL-12 tethered), and LN-145 Gen 3 (accelerated 16-day manufacturing). All TIL therapies are manufactured at the company's centralized 136,000 sq ft Iovance Cell Therapy Center (iCTC) in Philadelphia using proprietary Gen 2 processes.

Differentiator

Problem solved

Functional benefit

Brands

  • Amtagvi: FDA-approved tumor infiltrating lymphocyte therapy (lifileucel) for advanced melanoma. Product website: www.amtagvi.com
  • Proleukin
  • Iovance Cell Therapy Center (iCTC)
  • IovanceCares

Products and services

  • Amtagvi (lifileucel) One-time, tumor-derived autologous T-cell immunotherapy (TIL therapy) for adult patients with unresectable or metastatic melanoma previously treated with anti-PD-1 therapy and, if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. Manufactured at iCTC Philadelphia and administered at authorized treatment centers with NMA-LD lymphodepletion and IL-2 support.
  • Proleukin (aldesleukin) Interleukin-2 (IL-2) therapy used as supportive care within the TIL treatment regimen to promote T-cell activity and persistence after TIL infusion. Acquired from Clinigen and distributed by Iovance through authorized treatment centers globally alongside Amtagvi.
  • Lifileucel (LN-145) Investigational autologous TIL therapy being evaluated across multiple solid tumor indications beyond the approved advanced melanoma setting, supporting Iovance's pipeline-in-a-drug strategy.
  • IOV-4001 (PD-1 knockout TIL) Genetically modified autologous TIL therapy with the PD-1 gene inactivated using TALEN gene-editing technology licensed from Cellectis, designed to restore T-cell ability to kill cancer cells by avoiding checkpoint inhibition.
  • IOV-5001 (IL-12 tethered TIL) Next-generation IL-12 tethered TIL cell therapy designed to express IL-12 only upon antigen encounter within the tumor microenvironment and tether it to the cell membrane to avoid systemic toxicity, remodeling the tumor microenvironment into an immuno-supportive state.
  • LN-145 Gen 3 (16-day manufacturing) Third-generation TIL therapy using Iovance's proprietary 16-day GMP manufacturing process to reduce vein-to-vein time between tumor sample collection and infusion for patients, currently being explored in clinical trials.
  • IOV-3001 (modified IL-2 analog) Second-generation modified IL-2 fusion protein (modified aldesleukin fused to a humanized monoclonal IgG1K antibody) licensed from Novartis, designed to enhance TIL survival and cellular proliferation with a potentially better safety profile and less frequent dosing compared to Proleukin.

Quantifiable outcome

  • 44-52% objective response rate in advanced melanoma (real-world data), versus 31% in original C-144-01 clinical trial
  • +5 more outcomes

Companies that use Iovance Biotherapeutics

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles3 records

Iovance Biotherapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Iovance Biotherapeutics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core.

  • InspiroGene by McKessoncoreChannel Partner/ Reseller/ Distributor · 15 October 2025Specialty pharmacy partnership for Amtagvi product distribution in the United States. InspiroGene manages product fulfillment, cold chain logistics for the temperature-sensitive autologous cell therapy, and reimbursement support services.
  • Clinigen (Acquired Proleukin Rights)coreOEM/ Whitelabel/ Licensing Partner · 1 May 2023In May 2023, Iovance acquired worldwide rights to Proleukin (aldesleukin) from Clinigen to strengthen its T-cell immunotherapy programs for advanced melanoma patients. Proleukin is used as supportive care in TIL treatment regimens and is now distributed through Iovance's commercial infrastructure.
  • CellectiscoreTechnology or Integration · 1 January 2020In January 2020, Iovance and Cellectis entered into a research collaboration and worldwide license agreement enabling Iovance to use certain TALEN gene-editing technologies to modify TIL for therapeutic use in several cancer types. Iovance has a preclinical pipeline of TALEN-edited TIL therapies including double-knockout programs. This partnership enables development of next-generation gene-edited TIL products like IOV-4001 (PD-1 knockout TIL).
  • National Institutes of Health / National Cancer InstitutecoreStrategic or Co-development PartnerCooperative Research and Development Agreement (CRADA) with Dr. Steven Rosenberg for development of TIL therapy alone or in combination with other agents for metastatic melanoma, bladder, lung, breast, and HPV-associated cancers. Also includes TIL + anti-PD-1 combination clinical trial for melanoma treatment.
  • Moffitt Cancer CentercoreStrategic or Co-development PartnerTIL + anti-PD-1 antibody combination therapy clinical trial in non-small cell lung cancer (NSCLC). Also conducting TIL clinical trial in adolescents and young adults with soft tissue sarcoma.
  • The University of Texas MD Anderson Cancer CentercoreStrategic or Co-development PartnerTIL clinical trials to treat ovarian cancer, sarcomas, pancreatic cancer, and colorectal cancer. MD Anderson is one of the leading comprehensive cancer centers participating in Iovance's clinical development program.
  • Yale UniversitycoreStrategic or Co-development PartnerTIL clinical trial to treat triple-negative breast cancer (TNBC). Academic collaboration advancing TIL therapy in an area of high unmet medical need.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Iovance Biotherapeutics competitors and assessment

Company assessment

Broad incumbents

  • Novartis: Major pharmaceutical company with Kymriah (first FDA-approved CAR-T) and licensing partner for Iovance's IOV-3001 modified IL-2 analog. Broad incumbent in cell therapy with established manufacturing capabilities and competing immuno-oncology portfolio.
  • Merck & Co. Major pharmaceutical company with Keytruda (pembrolizumab) checkpoint inhibitor that Iovance combines with TIL therapy in TILVANCE-301. Broad incumbent and key strategic partner whose immuno-oncology franchise directly overlaps with Iovance's combination strategies.
  • Bristol Myers Squibb: Major pharmaceutical company with established CAR-T franchises (Breyanzi, Abecma) and checkpoint inhibitor (Opdivo) competing in melanoma. Broad incumbent in cell therapy and immuno-oncology with overlapping patient populations and significantly larger resources.
  • Gilead Sciences (Kite): Through its Kite Pharma subsidiary, Gilead markets Yescarta and Tecartus CAR-T therapies and is a leading cell therapy commercial organization. Broad incumbent with established autologous cell therapy manufacturing infrastructure and cell therapy experience applicable to Iovance's space.

Emerging players

  • Cellectis: Clinical-stage gene editing company developing allogeneic CAR-T and TALEN-edited cell therapies. Iovance's technology partner for PD-1 knockout TIL (IOV-4001), making it a strategic peer and indirect competitor in gene-edited cell therapies.
  • Lyell Immunopharma: Cell therapy company focused on solid tumor treatment with TIL and CAR-T programs, including technologies to prevent T-cell exhaustion. Emerging peer with overlapping technology focus on T-cell therapies for solid tumors.
  • Allogene Therapeutics: Leading allogeneic CAR-T developer pursuing off-the-shelf cell therapies. Represents a potential competitive threat if allogeneic approaches succeed in solid tumors, contrasting with Iovance's autologous model.

Direct peers

  • Turnstone Biologics: Clinical-stage biotech developing next-generation tumor-infiltrating lymphocyte (TIL) therapies for solid tumors, including selected TIL technology. Comparable as a TIL-focused competitor with similar autologous cell therapy development approach.
  • Instil Bio: Clinical-stage biotechnology company developing autologous TIL therapies (ITIL-306 and ITIL-168) for solid tumors. Direct peer in TIL therapy development with similar manufacturing platform and target indications in melanoma and other solid tumors.
  • Adaptimmune Therapeutics: Develops engineered T-cell therapies (SPEAR T-cells) for solid tumors using TCR technology. Directly comparable as a cell therapy company focused on solid tumor cancers with similar autologous manufacturing complexity and clinical development model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Iovance Biotherapeutics social profiles

Digital presence

Iovance Biotherapeutics compliance and trust

Trust signal

Compliance1 record

Iovance Biotherapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Iovance Biotherapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Iovance Biotherapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Iovance Biotherapeutics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Iovance Biotherapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iovance Biotherapeutics

What does Iovance Biotherapeutics do?

Iovance develops, manufactures, and commercializes autologous tumor infiltrating lymphocyte (TIL) cell therapies for the treatment of solid tumor cancers. Its flagship commercial product is Amtagvi (lifileucel), the first FDA-approved one-time T-cell therapy for solid tumors, indicated for advanced melanoma. The company also sells Proleukin (aldesleukin) as supportive care used within the TIL regimen, and is advancing a pipeline extending the same TIL platform to NSCLC, endometrial, cervical, head and neck, and soft tissue sarcoma indications.

Is Iovance Biotherapeutics a public or private company?

Iovance Biotherapeutics is a public company. It is classified as public and is currently operating.

When was Iovance Biotherapeutics founded?

Iovance Biotherapeutics was founded in 2016. It employs 501 to 1,000 people.

Where is Iovance Biotherapeutics based?

Iovance Biotherapeutics is headquartered in San Carlos, United States, in the North America region.

How does Iovance Biotherapeutics make money?

Two revenue lines are on record. Amtagvi (lifileucel) Sales are the primary driver. The others are proleukin (aldesleukin) Sales.

Who are Iovance Biotherapeutics's main competitors?

Broad incumbents on record are Novartis, Merck & Co., Bristol Myers Squibb and Gilead Sciences (Kite). Emerging players are Cellectis, Lyell Immunopharma and Allogene Therapeutics. Direct peers are Turnstone Biologics, Instil Bio and Adaptimmune Therapeutics.

Does Iovance Biotherapeutics have an API?

No public API is recorded for Iovance Biotherapeutics.

What industry is Iovance Biotherapeutics in?

Iovance Biotherapeutics's product category is Cell Therapy Immunotherapy. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Simply Wall StWhat Iovance Biotherapeutics Stock AMTAGVI Lung Cancer Push Means For ShareholdersIovance Biotherapeutics reported Q3 2026 revenue of $121.47 million and a net loss of $22.27 million, reaffirming full-year 2026 revenue guidance of $410–420 million. The company outlined 2027 price increases for Amtagvi and Proleukin and plans a second-line lung cancer indication for Amtagvi, with expansion to at least 110 treatment centers.Business & FinancialINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Iovance Biotherapeutics, Inc. - IOVAPomerantz Law Firm is investigating Iovance Biotherapeutics for potential securities fraud, following the company's October 29, 2026 Phase 2 trial results. Iovance reported data as 'consistent with previously reported results' rather than 'positive,' and its stock fell 35.45% to $9.56 per share.TradingViewIOVA: Revenue growth and 2027 lung, melanoma and sarcoma milestones drive the outlookIOVA reported Q3 revenue of $122M from AMTAGVI and PROLEUKIN, with FY2026 guidance of $410M-$420M. The company plans a 2027 lung sBLA, first-line melanoma work, and expanded sarcoma trials.PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVAPomerantz LLP is investigating Iovance Biotherapeutics for potential securities fraud, following a stock drop of 35.45% to $9.56 on October 29, 2026. The drop came after Iovance reported Phase 2 trial data for lifileucel as 'consistent with previously reported results,' with a subgroup response rate of 11.4% versus 12.8% for standard treatment.Business & FinancialCAPR Vs IBRX Vs SLS Vs IOVA: Whose Insiders Cashed Out The Most - And Who Bought Before A 5X Surge?Insiders at ImmunityBio and Capricor sold nearly $18 million in shares over the past year, with ImmunityBio's Barry Simon leading at $4.41 million. Sellas director Katherine Bach Kalin bought shares before the stock rose 5.3x, while Iovance insiders made no trades. Sellas' Regal trial reached its 80th death milestone, with results expected this quarter.StocktwitsCAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge?Insiders at ImmunityBio and Capricor sold nearly $18 million in shares over the past year, while Sellas director Katherine Bach Kalin bought shares that would have gained 430% if retained. Iovance insiders made no open-market trades, and Capricor awaits an FDA decision on its Duchenne application.TradingViewCAPR vs IBRX vs SLS vs IOVA: Whose Insiders Cashed Out The Most — And Who Bought Before A 5X Surge?Insiders at ImmunityBio and Capricor sold nearly $18 million in shares over the past year, with ImmunityBio director Barry Simon leading at $4.41 million. Sellas director Katherine Bach Kalin bought shares that gained 430% ahead of trial results, while Iovance insiders made no trades.Simply Wall StWill Earnings And Lung Cancer Data Change Iovance Stock NarrativeIovance Biotherapeutics reported Q3 2026 revenue of $121.47 million and a reduced net loss of $22.27 million, reaffirming full-year revenue guidance of $410–420 million. Updated lifileucel data in non-squamous metastatic NSCLC showed a 59.1% objective response rate in a biomarker-enriched subgroup, supporting its precision TIL approach.FinancialContent Business PageINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVAPomerantz LLP is investigating Iovance Biotherapeutics for potential securities fraud, following a stock drop after the company reported Phase 2 trial data as 'consistent with previously reported results' rather than 'positive.' The stock fell 35.45% to $9.56 per share on October 29, 2026.Seeking AlphaBiotech Is Booming; Here Are 4 Names Outperforming Despite This Deep CorrectionA biotech investor outlines a technical-analysis-based strategy for small-cap biotechs, citing four names that outperformed during a market correction. The stocks include Candel Therapeutics, Iovance Biotherapeutics, LB Pharmaceuticals, and TG Therapeutics, with details on their trial progress and price resilience.